Biomedical Engineering Reference
In-Depth Information
Angell M (2005) The truth about the drug companies: how they deceive us and what to do about
it. Random House Trade Paperbacks, New York
Avorn J, Solomon DH (2000) Cultural and economic factors that (mis)shape antibiotic use: the
nonpharmacologic basis of therapeutics. Ann Intern Med 133:128-135
Azoulay P (2002) Do pharmaceutical sales respond to scientifi c evidence? J Econ Manag Strat
11(4):551-594
Babor E, Ballinger BR, Fenton GW (1996) Infl uences on psychotropic drug prescription in a
psychiatric service. Psychiatr Bull 20:406-409
Bass FM (1969) A new product growth for model consumer durables. Manag Sci 15(5):215-227
Bass FM, Krishnan TV, Jain DC (1994) Why the Bass model fi ts without decision variables. Mark
Sci 13(3):203-223
Bass FM, Jain DC, Krishnan TV (2000) Modeling the marketing-mix infl uence in new-product
diffusion. In: Mahajan V, Muller E, Wind Y (eds) New-product diffusion models. Kluwer
Academic Publishers, Dordrecht, pp 99-122
Berndt ER, Bui L, Reiley DR, Urban GL (1995) Information, marketing, and pricing in the U.S.
anti-ulcer drug market. Am Econ Rev 85(2):100-105
Berndt ER, Bui L, Reiley DR, Urban GL (1997) The roles of marketing, product quality and price
competition in the growth and composition of the U.S. anti-ulcer drug industry. In: Bresnahan
TF, Gordon RJ (eds) The economics of new products. University of Chicago Press, Chicago,
pp 277-322
Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T (2002) An analysis of the diffusion
of new antidepressants: variety, quality, and marketing efforts. J Ment Health Policy Econ
5(1):3-19
Berndt ER, Kyle MK, Ling DC (2003a) The long shadow of patent expiration: generic entry and
RX-to-OTC switches. In: Feenstra RC, Shapiro MD (eds) Scanner data and price indexes.
University of Chicago Press, Chicago, pp 229-274
Berndt ER, Pindyck RS, Azoulay P (2003b) Consumption externalities and diffusion in pharma-
ceutical markets: anti-ulcer drugs. J Ind Econ 51(2):243-270
Bhattacharya J, Vogt WB (2003) A simple model of pharmaceutical price dynamics. J Law Econ
23(2):599-626
Bowman D, Gatignon H (1996) Order of entry as a moderator of the effect of the marketing mix
on market share. Mark Sci 15(3):222-242
Calfee JE (2002) Public policy issues in direct-to-consumer advertising of prescription drugs.
J Public Policy Mark 21(2):174-193
Calfee JE, Winston C, Stempski R (2002) Direct-to-consumer advertising and the demand for
cholesterol-reducing drugs. J Law Econ 45(10):673-690
Camacho N, Landsman V, Stremersch S (2010) The connected patient. In: Wuyts S, Dekimpe M,
Gijsbrechts E, Pieters R (eds) The connected customer: the changing nature of consumer and
business markets. Routledge Academic, New York, pp 107-139
Chandrasekaran D, Tellis GJ (2007) A critical review of marketing research on diffusion of new
products. In: Malhotra NK (ed) Review of marketing research, vol 3. M.E. Sharpe, Armonk,
NY, pp 39-80
Chatterjee R, Eliashberg J (1990) The innovation diffusion process in heterogeneous population:
a micromodeling approach. Manag Sci 36(9):1057-1079
Chetley A (1995) Problem drugs. Health Action International, Amsterdam
Ching A, Ishihara M (2010) The effects of detailing on prescribing decisions under quality uncer-
tainty. Quant Mark Econ 8(2):123-165
Chintagunta PK, Desiraju R (2005) Strategic pricing and detailing behavior in international
markets. Mark Sci 24(1):67-80
CMS (2011) National Health Expenditures 2009 highlights.
https://www.cms.gov/NationalHealth
ExpendData/downloads/highlights.pdf
.
Accessed 13 July 2011
Coscelli A (2000) The importance of doctors' and patients' preferences in the prescription
decision. J Ind Econ 48(3):349-369
Search WWH ::
Custom Search